This study successfully validated our central hypothesis that combining ALA and metformin therapy provides synergistic neuroprotection in diabetic encephalopathy through the coordinated activation of Nrf2 and AMPK signaling pathways. This evidence concerns the gene NFE2L2 and diabetic encephalopathy.